Compare Globus Medical Inc. Class A Common Stock (GMED) vs VF Corp (VFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs VF Corp — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while VF Corp trades at $16.52 (market cap $6.32B). The key difference: Globus Medical Inc. Class A Common Stock is the larger of the two by market cap, and VF Corp pays a 2.24% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and VF Corp for 64 Days on average.
| GMED | VFC | |
|---|---|---|
Market Cap | $10.25B | $6.32B |
Volume | 1,108,124 | 14,983,623 |
Sector | Health | Consumer Cyclical |
52-Week High | $96.82 | $21.55 |
52-Week Low | $58.33 | $12.62 |
Typical Hold Time | 0 Days | 64 Days |
Enterprise Value | $9.76B | $10.60B |
Dividend Yield | — | 2.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
VFC trades at $16.48, up 4.37% today, with a bullish technical signal and a consensus analyst price target of $18.33. Recent earnings show mixed results, with a Q4 2025 beat but Q1 and Q2 2026 misses. Revenue declined to $9.5B in 2025, with a net loss of $189.72M, though 2026 projects a return to profitability. The company maintains a strong gross margin of 54.97% but faces challenges from high debt and weak performance in its Vans brand.
The outlook is cautiously optimistic, supported by valuation discounts (P/S 0.67) and growth in outdoor brands, but execution risk on the Vans turnaround and high leverage pose significant threats. Near-term price action is buoyed by technical momentum, yet fundamental recovery hinges on sustained revenue improvement and debt reduction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
